

**INDRAYANI BIOTECH LIMITED**

Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.

Telefax: 020 - 25662021, Web: [www.indrayani.com](http://www.indrayani.com), Email: [info@indrayani.com](mailto:info@indrayani.com), CIN: L24231PN1992PLC065801

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2017**

PARTICULARS	Quarter Ended			Rs. In Lakhs Year Ended	
	31 <sup>st</sup> March, 2017	31 <sup>st</sup> December, 2016	31 <sup>st</sup> March, 2016	31 <sup>st</sup> March, 2017	31 <sup>st</sup> March, 2016
	<b>Income</b>				
Revenue from Operations	-	-	-	-	-
Other Income	-	-	-	-	-
<b>Total Income</b>					
<b>Expenses</b>					
Cost of Materials consumed	-	-	-	-	-
Purchase of stock-in-trade	-	-	-	-	-
Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
Employee benefits expenses	1.10	0.60	0.80	2.70	1.97
Finance Cost	-	-	-	-	-
Depreciation and amortisation expense	-	-	-	-	-
Other expenses	1.23	1.70	2.39	7.69	10.95
<b>Total Expenses</b>	<b>2.33</b>	<b>2.30</b>	<b>3.19</b>	<b>10.39</b>	<b>12.92</b>
<b>Profit / (Loss) before exceptional and extraordinary items and tax</b>	<b>(2.33)</b>	<b>(2.30)</b>	<b>(3.19)</b>	<b>(10.39)</b>	<b>(12.92)</b>
Exceptional Items	-	-	-	-	-
<b>Profit / (Loss) before extraordinary items and tax</b>	<b>(2.33)</b>	<b>(2.30)</b>	<b>(3.19)</b>	<b>(10.39)</b>	<b>(12.92)</b>
Extraordinary items	-	-	-	-	-
<b>Profit / (Loss) before tax</b>	<b>(2.33)</b>	<b>(2.30)</b>	<b>(3.19)</b>	<b>(10.39)</b>	<b>(12.92)</b>
<b>Tax expense</b>					
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	-
<b>Profit / (Loss) for the period</b>	<b>(2.33)</b>	<b>(2.30)</b>	<b>(3.19)</b>	<b>(10.39)</b>	<b>(12.92)</b>
<b>Other Comprehensive Income (OCI)</b>					
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period).	-	-	-	-	-
<b>Earnings per share (for continuing operation) :</b>					
Basic:	(0.06)	(0.06)	(0.09)	(0.28)	(0.35)
Diluted:	(0.06)	(0.06)	(0.09)	(0.28)	(0.35)
<b>Earnings per share (for discontinued operation) :</b>					
Basic:	-	-	-	-	-
Diluted:	-	-	-	-	-

INDRAYANI BIOTECH LTD.

*(Signature)*  
MANAGING DIRECTOR



Earnings per share (for discontinued & continuing operation):					
Basic:	(0.06)	(0.06)	(0.09)	(0.28)	(0.35)
Diluted:	(0.06)	(0.06)	(0.09)	(0.28)	(0.35)

**Notes:**

1. The statutory auditors of the Company have audited the above financial results, the same have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 27<sup>th</sup> May, 2017.
2. The Company operates in a single business segment - Travel Technology & Support Services. Hence, no segment wise figures are published.
3. The above financial results are available on the website of the Company - [www.Indrayani.com](http://www.Indrayani.com)

For Indrayani Biotech Limited



Prakash Bang  
Managing Director  
DIN: 00088837



Date: 27<sup>th</sup> May, 2017  
Place: Pune



**STATEMENT OF ASSETS AND LIABILITIES FOR THE YEAR ENDED 31ST MARCH 2017.**

(Rs. in Lakhs)

<b>Standalone Statement of Assets and Liabilities</b>	<b>Current year ended 31/03/2017</b>	<b>Previous year ended 31/03/2016</b>
<b>Particulars</b>		
<b>ASSETS</b>		
Non-current assets	-	-
Property, Plant & Equipment	-	-
Capital Work in Progress	-	-
Investment Property	-	-
Goodwill	349.97	349.97
Other Intangible Assets	-	-
Intangible Assets under development	-	-
Property, Plant & Equipment	-	-
Biological assets other than bearer plants	-	-
Financial Assets	-	-
Investments	-	-
Trade receivables	-	-
Loans	-	-
Others (to be specified)	-	-
<b>Current Assets</b>		
Inventories	-	-
Financial Assets	-	-
Investments	-	-
Trade Receivables	-	-
Cash & Cash Equivalents	0.22	3.03
Bank Balances other than above	-	-
Loans	-	-
Others (to be specified)	-	-
<b>Total Assets</b>	<b>350.19</b>	<b>353.00</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity Share Capital	364.39	364.39
Other Equity	(62.15)	(51.77)
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial Liabilities	-	-
Borrowings	47.50	40.00
Trade Payables	-	-
Other Financial liabilities	-	-
Provisions	-	-
Deferred Tax liabilities (net)	-	-
Other Non-current liabilities	-	-
<b>Current liabilities</b>		
Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	0.22	-
Other Financial liabilities	-	-
Provisions	0.23	0.38
Current Tax liabilities (Net)	-	-
<b>Total Equity and Liabilities</b>	<b>350.19</b>	<b>353.00</b>

**INDRAYANI BIOTECH LTD.**

*(Signature)*  
**MANAGING DIRECTOR**





Ref. No. :

Date :

**Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of Indrayani Biotech Limited

We have audited the quarterly financial results of Indrayani Biotech Limited for the quarter ended 31<sup>st</sup> March, 2017 and the year to date results for the period April 1, 2016 to March 31, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net loss and other financial information for the quarter ended March 31, 2017 (date of the quarter end) as well as the year to date results for the period from April 1, 2016 to March 31, 2017.

For G.V.Madane and Company  
Chartered Accountants  
FRN No. – 105698W



*Anup A-Tabe*

Anup A-Tabe – Partner  
(Membership Number 164449)

Place of signature: Pune

Date: 27/05/2017